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Abstract Infection with Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012 as an
important respiratory disease with high fatality rates of 40%–60%. Despite the increased number of cases over
subsequent years, the number of pediatric cases remained low. A review of studies conducted from June 2012 to
April 19, 2016 reported 31 pediatric MERS-CoV cases. In this paper, we present the clinical and laboratory
features of seven patients with pediatric MERS. Five patients had no underlying medical illnesses, and three
patients were asymptomatic. Of the seven cases, four (57%) patients sought medical advice within 1–7 days from
the onset of symptoms. The three other patients (43%) were asymptomatic and were in contact with patients with
confirmed diagnosis of MERS-CoV. The most common presenting symptoms were fever (57%), cough (14%),
shortness of breath (14%), vomiting (28%), and diarrhea (28%). Two (28.6%) patients had platelet counts of < 150
 109/L, and one patient had an underlying end-stage renal disease. The remaining patients presented with
normal blood count, liver function, and urea and creatinine levels. The documented MERS-CoV Ct values were
32–38 for four of the seven cases. Two patients (28.6%) had abnormal chest radiographic findings of bilateral
infiltration. One patient (14.3%) required ventilator support, and two patients (28.6%) required oxygen
supplementation. All the seven patients were discharged without complications.
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Introduction
Middle East respiratory syndrome coronavirus (MERS-
CoV) was initially described and detected in 2012 in a
patient from the Kingdom of Saudi Arabia (KSA) [1].
Infection with this virus exhibits high fatality rates of
40%–60% [2–5]. The number of cases affected with
MERS-CoV reached 2015, and 703 patients died of the
resulting disease [6]. The hallmark of the disease is the
predominance of transmission in health-care settings
[2,3,7–13], where human-to-human transmission is the
main route of transmission and causes the majority of
cases. In community settings, the transmission of MERS-
CoV has been believed to occur from dromedary camels to
humans. Community transmissions also occur in house-
hold settings [14]. Another feature of the disease is the
occurrence of few cases among children [4,15]. The first
reported case in the pediatric age group involved a child
from Jeddah, KSA on June 28, 2013 [16]. A recent review
included 31 pediatric MERS-CoV cases within a 5-year
period [17]. In a study on 2235 children with acute viral
respiratory infections, none was tested positive for MERS-
CoV [18]. From 2012 to 2015 in KSA, a total of 1250
patients were reported to have MERS-CoV infection, and
3.3% of them aged less than 10 years [19]. In another
analysis of 109 cases between April 23, 2014 and August
31, 2015, 4.2% of the patients aged less than 20 years [20].
From April 2015 to February 2016, 57 363 residents (18.4/
10 000) were suspected with and tested positive for
MERS-CoV infection in KSA, and only 0.7% was tested
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positive for MERS-CoV infection [21]. In the same period,
10 (0.1%) of 8032 children aged less than 14 years were
positive for MERS-CoV [21]. In 2015, the case definition
included a specific description of children who needed
testing and those who were exposed to camels or camel
products or to a confirmed or suspected MERS case and
children with unexplained severe pneumonia [22]. In this
paper, we present the clinical and laboratory features of
seven pediatric patients.
Presentation of cases
We collected the clinical and laboratory data of pediatric
patients admitted to Prince Mohamed Bin Abdulaziz
Hospital (PMAH), Ministry of Health, Riyadh, KSA.
Nasopharyngeal swabs (NPSs) were tested for MERS-
CoV by using real-time reverse-transcriptase polymerase
chain reaction (RT-PCR) as described previously
[4,23,24]. The PCR test amplifies the upstream E protein
(upE gene) and ORF1a of MERS-CoV. A positive test was
considered when both assays were positive, and the
samples were considered negative when the MERS-CoV
RT-PCR was negative [4].
From April 2014 to November 2016, 295 patients of
definite MERS were admitted to PMAH. Of these patients,
seven (2.4%) were children ( < 18 years) (Table 1), and
57% were female aged between 8 months and 16 years.
One patient had bronchial asthma and chronic renal
disease, and another patient had sickle cell disease. The
five other cases had no underlying illnesses.
Of the seven cases, four patients sought medical advice
within 1–7 days from the onset of symptoms. The other
three (43%) patients were asymptomatic and were in
contact with confirmed patients who acquired MERS-CoV.
The most common presenting symptoms were fever
(57%), cough (14%), shortness of breath (14%), diarrhea
(28%), and vomiting (28%) (Fig. 1).
Of the seven cases, two (28.6%) cases had platelet
counts of < 150  109/L, and one had an elevated
creatinine level due to an underlying ESRD. The rest of the
patients had normal blood count, liver function test, and
urea and creatinine levels (Table 2). The documented
MERS-CoV Ct values were 32–38 for four of the seven
cases.
Two (28.6%) patients had abnormal chest radiographic
findings of bilateral infiltration (Fig. 2). One (14.3%)
required ventilatory support, and two (28.6%) required
supplemental oxygen. All the seven patients were
discharged without complications.
Table 1 Summary of clinical presentation and outcome of pediatric MERS-CoV cases
Number
Age
(years)
Gender Symptom Comorbidity CXR finding
Intensive care
unit
Days of illness
before
hospitalization
Linked to O2 requirement
1 16 Male Fever, SOB,
diarrhea,
vomiting
ESRD, asthma Pneumonic
infiltration
YES 2 Contact with
confirmed case
6 days
2 10 Female Fever, cough,
vomiting,
diarrhea
NO Normal NO 7 NA Nil
3 13 Female Fever Miliary TB Bilateral diffuse NO 2 NA 12 days
4 6 Female Fever NO Normal NO 1 No Nil
5 0.75 Male Asymptomatic NO Normal NO Asymptomatic Mother and
grandmother
confirmed cases
Nil
6 9 Female Asymptomatic Sickle cell anemia Normal NO Asymptomatic NA Nil
7 1.5 Male Asymptomatic NO Normal NO Asymptomatic Mother
confirmed case
Nil
ESRD, end-stage renal disease; NPS, nasopharyngeal swab; POS, positive; SOB, shortness of breath; CXR, chest X-ray; TB, tuberculosis; NA, not available.
Fig. 1 Graph showing the most common clinical findings (percentage)
among the presented pediatric MERS-CoV cases.
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Discussion
One characteristic feature of MERS-CoV is the extremely
low number of children who were affected by the disease.
In this report, we found a low rate of pediatric MERS-CoV
infection and constituted only 2.4% of all admitted patients
to this MERS-CoV referral hospital. The prevalence of
MERS-CoV among children and adults was evaluated in
two large studies. In a contact screening of 616 children,
only nine (1.9%) children were positive compared with
2.2% among 4440 adults ( > 17 years of age) [25]. In a
second study, children ( < 14 years of age) had positive
MERS-CoV by PCR test in 10 of 8032 (0.1%) compared
with 372 of 48 386 (0.7%) [21]. In adults, the pattern of
MERS infection could be sporadic cases, health-care-
associated infection or transmission within families [26].
In contrast to infection in adults where health-care-
associated infection is predominant [26], most confirmed
pediatric cases were related secondary to exposure to other
MERS-CoV cases within the same family [17]. The
female-to-male ratio in childhood MERS-CoV was 1:1.7
[17], which is not similar to the ratio obtained in this study.
The clinical presentation of MERS in adults ranges from
asymptomatic to fatal and severe cases [26–28]. By
contrast, the course of pediatric MERS cases is usually
mild or asymptomatic [17].
Considering that MERS-CoV is a respiratory disease,
the most common symptoms in adults were respiratory in
nature [26]. In this small case series, fever was the
predominant symptom (57%), followed by vomiting
(28%), diarrhea (28%), cough (14%), and shortness of
breath (14%). Gastrointestinal symptoms were also
common manifestations among adult patients [4,26,29].
Variable hematologic and hepatic panel findings were
described among adult patients with MERS-CoV and
indicated conditions, such as thrombocytopenia and
thrombocytosis [30]. In this report, two (28.6%) patients
had thrombocytopenia, and the other patients had normal
blood count and liver function test. Chronic renal disease
was observed in only one patient in the current series, and
renal dysfunction was a major pre-existing disease in
adults [3]. In this report, all patients were discharged
without complications. In the previous review of 31
pediatric cases, the fatality rate was 33.3% [17].
The occurrence of mild diseases in the pediatric age
group has no clear explanation. Possible explanations for
these findings include low exposure of pediatrics to
MERS-CoV, presence of asymptomatic children and
mildly symptomatic patients, or the existence of unidenti-
fied factors [17]. The manifestation of MERS as asympto-
matic or mildly symptomatic may lead to under-detection
due to low clinical suspicion. Whether any correlation
exists between the occurrence of MERS in children and
associated immunological factors is not known. In adults,
serologic responses were not detected in asymptomatic
infection but were 60%, 93.8%, and 100% in symptomatic
Table 2 Laboratory data on presentation of pediatric MERS-CoV cases
Number Viral Ct value WBC Hgb Plat Neut count Neut % CK ALT AST Creat Albumin
1 NA 6.1 91 58 4.95 81.0 169 37 91 1256.1 NA
2 37 3.8 149 145 0.18 4.6 NA NA NA NA 34
3 32 3 90 467 2.25 70.6 NA 6 71 44 26
4 36 8.6 138 500 5.14 60.0 NA NA NA NA 41
5 NA 17.9 105 406 1.93 10.8 62 NA NA 36.3 NA
6 38 13.3 77 352 9.19 69.2 NA NA NA NA 44
7 NA 11 113 383 2.16 19.6 NA 23 42 NA 45
WBC, white blood cell; Hgb, hemoglobin; Plat, platelet; Neut, neutrophil; CK, creatinine kinase; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; Creat, creatinine; NA, not available.
Fig. 2 Portable chest X-ray showing bilateral mid and lower
zone patchy air space consolidation with mild right-sided pleural
effusion. R, right side.
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patients without pneumonia, pneumonia without respira-
tory failure, and with pneumonia and respiratory failure,
respectively [31]. For adult patients with MERS-CoV,
longer intensive care unit stays and more prolonged virus
shedding were associated with CD4+ T-cell responses
compared with those of children [32]. In animal model, the
development of specific CD8+ Tcell and virus-neutralizing
antibodies may result in protection against MERS-CoV
[33–36]. Thus, children may have a different immunologic
response with less CD4+ T-cell responses, resulting in a
lower rate of and less severe infection compared with
adults. Further studies are needed to better understand
pediatric MERS-CoV in terms of clinical presentation,
infectivity, and outcome.
Conclusions
MERS-CoV remains an uncommon disease among
children, and its course follows a milder path among
children than those of adults. Majority of cases were
asymptomatic and were diagnosed during the course of
contact investigation.
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